{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T20:59:26Z","timestamp":1774126766284,"version":"3.50.1"},"publisher-location":"Cham","reference-count":97,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319479330","type":"print"},{"value":"9783319479354","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T00:00:00Z","timestamp":1481587200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-47935-4_12","type":"book-chapter","created":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T05:01:24Z","timestamp":1481518884000},"page":"269-294","source":"Crossref","is-referenced-by-count":5,"title":["Phages Against Infectious Diseases"],"prefix":"10.1007","author":[{"given":"Lu\u00eds D. R.","family":"Melo","sequence":"first","affiliation":[]},{"given":"Hugo","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"S\u00edlvio B.","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Sanna","family":"Sillankorva","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Azeredo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,12,13]]},"reference":[{"key":"12_CR1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12941-014-0039-z","volume":"13","author":"AS Abdulamir","year":"2014","unstructured":"Abdulamir AS, Jassim SA, Abu Bakar F (2014) Novel approach of using a cocktail of designed bacteriophages against gut pathogenic E. coli for bacterial load biocontrol. Ann Clin Microbiol Antimicrob 13:39","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/138920110790725410","volume":"11","author":"ST Abedon","year":"2010","unstructured":"Abedon ST, Thomas-Abedon C (2010) Phage therapy pharmacology. Curr Pharm Biotechnol 11:28\u201347","journal-title":"Curr Pharm Biotechnol"},{"key":"12_CR3","first-page":"8","volume-title":"The bacteriophages","author":"H-W Ackermann","year":"2006","unstructured":"Ackermann H-W (2006) Classification of bacteriophages. In: Calendar R (ed) The bacteriophages. Oxford University Press, New York, pp. 8\u201316"},{"key":"12_CR4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00705-006-0849-1","volume":"152","author":"HW Ackermann","year":"2007","unstructured":"Ackermann HW (2007) 5500 Phages examined in the electron microscope. Arch Virol 152:227\u2013243","journal-title":"Arch Virol"},{"key":"12_CR5","doi-asserted-by":"crossref","first-page":"e00029","DOI":"10.1128\/mBio.00029-12","volume":"3","author":"D Alemayehu","year":"2012","unstructured":"Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG et al (2012) Bacteriophages phiMR299-2 and phiNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 3:e00029\u2013e00012","journal-title":"MBio"},{"key":"12_CR6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1472-765X.2003.01262.x","volume":"36","author":"G Bachrach","year":"2003","unstructured":"Bachrach G, Leizerovici-Zigmond M, Zlotkin A, Naor R, Steinberg D (2003) Bacteriophage isolation from human saliva. Lett Appl Microbiol 36:50\u201353","journal-title":"Lett Appl Microbiol"},{"key":"12_CR7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0966-842X(97)01054-8","volume":"5","author":"PA Barrow","year":"1997","unstructured":"Barrow PA, Soothill JS (1997) Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol 5:268\u2013271","journal-title":"Trends Microbiol"},{"key":"12_CR8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1023\/A:1007957911848","volume":"16","author":"H Brussow","year":"1998","unstructured":"Brussow H, Bruttin A, Desiere F, Lucchini S, Foley S (1998) Molecular ecology and evolution of Streptococcus thermophilus bacteriophages \u2013 a review. Virus Genes 16:95\u2013109","journal-title":"Virus Genes"},{"key":"12_CR9","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1128\/AAC.49.7.2874-2878.2005","volume":"49","author":"A Bruttin","year":"2005","unstructured":"Bruttin A, Brussow H (2005) Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49:2874\u20132878","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1128\/AAC.05842-11","volume":"56","author":"JJ Bull","year":"2012","unstructured":"Bull JJ, Otto G, Molineux IJ (2012) In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model. Antimicrob Agents Chemother 56:949\u2013954","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR11","first-page":"752930","volume":"2015","author":"F Cao","year":"2015","unstructured":"Cao F, Wang X, Wang L, Li Z, Che J et al (2015a) Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. Biomed Res Int 2015:752930","journal-title":"Biomed Res Int"},{"key":"12_CR12","doi-asserted-by":"crossref","unstructured":"Cao Z, Zhang J, Niu YD, Cui N, Ma Y, et al. (2015b) Isolation and characterization of a \u201cphiKMV-like\u201d bacteriophage and its therapeutic effect on mink hemorrhagic pneumonia. PLoS One 10: e0116571.","DOI":"10.1371\/journal.pone.0116571"},{"key":"12_CR13","first-page":"267","volume":"47","author":"RM Carlton","year":"1999","unstructured":"Carlton RM (1999) Phage therapy: past history and future prospects. Arch Immunol Ther Exp (Warsz) 47:267\u2013274","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"12_CR14","doi-asserted-by":"crossref","first-page":"e56022","DOI":"10.1371\/journal.pone.0056022","volume":"8","author":"S Chhibber","year":"2013","unstructured":"Chhibber S, Kaur T, Sandeep K (2013) Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS One 8:e56022","journal-title":"PLoS One"},{"key":"12_CR15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12866-014-0212-8","volume":"14","author":"S Chhibber","year":"2014","unstructured":"Chhibber S, Gupta P, Kaur S (2014) Bacteriophage as effective decolonising agent for elimination of MRSA from anterior nares of BALB\/c mice. BMC Microbiol 14:212","journal-title":"BMC Microbiol"},{"key":"12_CR16","first-page":"373","volume":"165","author":"F d\u2019Herelle","year":"1917","unstructured":"d\u2019Herelle F (1917) Sur un microbe invisible antagoniste des bacilles dysent\u00e9riques. CR Acad Sci Paris 165:373\u2013375","journal-title":"CR Acad Sci Paris"},{"key":"12_CR17","doi-asserted-by":"crossref","unstructured":"d\u2019Herelle F (1926) The bacteriophage and its behaviour. In: d\u02bcHerelle F (ed). The Williams & Wilkins Company, Baltimore","DOI":"10.5962\/bhl.title.7308"},{"key":"12_CR18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2672.2004.02422.x","volume":"98","author":"K Dabrowska","year":"2005","unstructured":"Dabrowska K, Switala-Jelen K, Opolski A, Weber-Dabrowska B, Gorski A (2005) Bacteriophage penetration in vertebrates. J Appl Microbiol 98:7\u201313","journal-title":"J Appl Microbiol"},{"key":"12_CR19","doi-asserted-by":"crossref","first-page":"396165","DOI":"10.1155\/2012\/396165","volume":"2012","author":"JJ Dennehy","year":"2012","unstructured":"Dennehy JJ (2012) What can phages tell us about host-pathogen coevolution? Int J Evol Biol 2012:396165","journal-title":"Int J Evol Biol"},{"key":"12_CR20","first-page":"625","volume":"12","author":"L Diomede","year":"2001","unstructured":"Diomede L, Albani D, Bianchi M, Salmona M (2001) Endotoxin regulates the maturation of sterol regulatory element binding protein-1 through the induction of cytokines. Eur Cytokine Netw 12:625\u2013630","journal-title":"Eur Cytokine Netw"},{"key":"12_CR21","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1097\/CCM.0000000000000968","volume":"43","author":"N Dufour","year":"2015","unstructured":"Dufour N, Debarbieux L, Fromentin M, Ricard JD (2015) Treatment of highly virulent extraintestinal pathogenic Escherichia coli pneumonia with bacteriophages. Crit Care Med 43:e190\u2013e198","journal-title":"Crit Care Med"},{"key":"12_CR22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1128\/AAC.00669-09","volume":"54","author":"W Fu","year":"2010","unstructured":"Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM et al (2010) Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 54:397\u2013404","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR23","doi-asserted-by":"crossref","first-page":"e47742","DOI":"10.1371\/journal.pone.0047742","volume":"7","author":"K Fukuda","year":"2012","unstructured":"Fukuda K, Ishida W, Uchiyama J, Rashel M, Kato S et al (2012) Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration. PLoS One 7:e47742","journal-title":"PLoS One"},{"key":"12_CR24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/138920110790725311","volume":"11","author":"JJ Gill","year":"2010","unstructured":"Gill JJ, Hyman P (2010) Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol 11:2\u201314","journal-title":"Curr Pharm Biotechnol"},{"key":"12_CR25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/138920110790725348","volume":"11","author":"LD Goodridge","year":"2010","unstructured":"Goodridge LD (2010) Designing phage therapeutics. Curr Pharm Biotechnol 11:15\u201327","journal-title":"Curr Pharm Biotechnol"},{"key":"12_CR26","first-page":"766","volume":"10","author":"A Gorski","year":"2009","unstructured":"Gorski A, Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Lobocka M et al (2009) Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs 10:766\u2013774","journal-title":"Curr Opin Investig Drugs"},{"key":"12_CR27","doi-asserted-by":"crossref","first-page":"e31698","DOI":"10.1371\/journal.pone.0031698","volume":"7","author":"J Gu","year":"2012","unstructured":"Gu J, Liu X, Li Y, Han W, Lei L et al (2012) A method for generation phage cocktail with great therapeutic potential. PLoS One 7:e31698","journal-title":"PLoS One"},{"key":"12_CR28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00284-010-9699-x","volume":"62","author":"R Gupta","year":"2011","unstructured":"Gupta R, Prasad Y (2011) Efficacy of polyvalent bacteriophage P-27\/HP to control multidrug resistant Staphylococcus aureus associated with human infections. Curr Microbiol 62:255\u2013260","journal-title":"Curr Microbiol"},{"key":"12_CR29","volume-title":"Bacteriophages \u2013 biology and applications","author":"B Guttman","year":"2005","unstructured":"Guttman B, Raya R, Kutter E (2005) Basic phage biology. In: Kutter E, Sulakvelidze A (eds) Bacteriophages \u2013 biology and applications. CRC Press, Boca Raton"},{"key":"12_CR30","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1128\/AAC.48.10.3817-3822.2004","volume":"48","author":"S Hagens","year":"2004","unstructured":"Hagens S, Habel A, von Ahsen U, von Gabain A, Blasi U (2004) Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 48:3817\u20133822","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR31","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1128\/AEM.00757-12","volume":"78","author":"AR Hall","year":"2012","unstructured":"Hall AR, De Vos D, Friman VP, Pirnay JP, Buckling A (2012) Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl Environ Microbiol 78:5646\u20135652","journal-title":"Appl Environ Microbiol"},{"key":"12_CR32","first-page":"511","volume":"10","author":"EH Hankin","year":"1896","unstructured":"Hankin EH (1896) L\u2019action bactericide des eaux de la Jumna et du Gange sur le vibrion du cholera. Ann Inst Pasteur 10:511","journal-title":"Ann Inst Pasteur"},{"key":"12_CR33","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-230-55228-9","volume-title":"Viruses vs. superbugs \u2013 a solution to the antibiotic crisis?","author":"T H\u00e4usler","year":"2006","unstructured":"H\u00e4usler T (2006) Viruses vs. superbugs \u2013 a solution to the antibiotic crisis? Macmillan, New York"},{"key":"12_CR34","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1128\/AAC.01596-13","volume":"57","author":"M Henry","year":"2013","unstructured":"Henry M, Lavigne R, Debarbieux L (2013) Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother 57:5961\u20135968","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1472-765X.2004.01565.x","volume":"39","author":"G Hitch","year":"2004","unstructured":"Hitch G, Pratten J, Taylor PW (2004) Isolation of bacteriophages from the oral cavity. Lett Appl Microbiol 39:215\u2013219","journal-title":"Lett Appl Microbiol"},{"key":"12_CR36","doi-asserted-by":"crossref","unstructured":"Holzheimer RG (2001) Antibiotic induced endotoxin release and clinical sepsis: a review. J Chemother 13 Spec No 1: 159\u2013172","DOI":"10.1179\/joc.2001.13.Supplement-2.159"},{"key":"12_CR37","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1128\/AAC.01123-10","volume":"55","author":"CH Hung","year":"2011","unstructured":"Hung CH, Kuo CF, Wang CH, Wu CM, Tsao N (2011) Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob Agents Chemother 55:1358\u20131365","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR38","doi-asserted-by":"crossref","first-page":"e1003844","DOI":"10.1371\/journal.pgen.1003844","volume":"9","author":"W Jiang","year":"2013","unstructured":"Jiang W, Maniv I, Arain F, Wang Y, Levin BR et al (2013) Dealing with the evolutionary downside of CRISPR immunity: bacteria and beneficial plasmids. PLoS Genet 9:e1003844","journal-title":"PLoS Genet"},{"key":"12_CR39","doi-asserted-by":"crossref","unstructured":"Johnson AP (2015) Surveillance of antibiotic resistance. Philos Trans Royal Soc B-Biol Sci 370","DOI":"10.1098\/rstb.2014.0080"},{"key":"12_CR40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0378-1119(02)01076-4","volume":"299","author":"M Kakikawa","year":"2002","unstructured":"Kakikawa M, Yokoi K, Kimoto H, Nakano M, Kawasaki KI et al (2002) Molecular analysis of the lysis protein Lys encoded by Lactobacillus plantarum phage theta g1e. Gene 299:227\u2013234","journal-title":"Gene"},{"key":"12_CR41","first-page":"238","volume":"3","author":"EC Keen","year":"2012","unstructured":"Keen EC (2012) Phage therapy: concept to cure. Front Microbiol 3:238","journal-title":"Front Microbiol"},{"key":"12_CR42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1751-7915.2008.00028.x","volume":"1","author":"KP Kim","year":"2008","unstructured":"Kim KP, Cha JD, Jang EH, Klumpp J, Hagens S et al (2008) PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microb Biotechnol 1:247\u2013257","journal-title":"Microb Biotechnol"},{"key":"12_CR43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s10753-010-9253-9","volume":"34","author":"V Kumar","year":"2011","unstructured":"Kumar V, Chhibber S (2011) Acute lung inflammation in Klebsiella pneumoniae B5055-induced pneumonia and sepsis in BALB\/c mice: a comparative study. Inflammation 34:452\u2013462","journal-title":"Inflammation"},{"key":"12_CR44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1099\/jmm.0.018580-0","volume":"60","author":"S Kumari","year":"2011","unstructured":"Kumari S, Harjai K, Chhibber S (2011) Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. J Med Microbiol 60:205\u2013210","journal-title":"J Med Microbiol"},{"key":"12_CR45","doi-asserted-by":"crossref","unstructured":"Kutter E, Raya R, Carlson K (2005) Molecular mechanisms of phage infection. In: Kutter E, Sulakvelidze A, (eds). CRC Press","DOI":"10.1201\/9780203491751.ch7"},{"key":"12_CR46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/138920110790725401","volume":"11","author":"E Kutter","year":"2010","unstructured":"Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L et al (2010) Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11:69\u201386","journal-title":"Curr Pharm Biotechnol"},{"key":"12_CR47","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2217\/fmb.15.28","volume":"10","author":"EM Kutter","year":"2015","unstructured":"Kutter EM, Kuhl SJ, Abedon ST (2015) Re-establishing a place for phage therapy in western medicine. Future Microbiol 10:685\u2013688","journal-title":"Future Microbiol"},{"key":"12_CR48","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/AEM.02675-13","volume":"80","author":"HS Lee","year":"2014","unstructured":"Lee HS, Choi S, Shin H, Lee JH, Choi SH (2014) Vibrio vulnificus bacteriophage SSP002 as a possible biocontrol agent. Appl Environ Microbiol 80:515\u2013524","journal-title":"Appl Environ Microbiol"},{"key":"12_CR49","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrmicro822","volume":"2","author":"BR Levin","year":"2004","unstructured":"Levin BR, Bull JJ (2004) Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2:166\u2013173","journal-title":"Nat Rev Microbiol"},{"key":"12_CR50","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4161\/bact.1.2.14590","volume":"1","author":"C Loc-Carrillo","year":"2011","unstructured":"Loc-Carrillo C, Abedon ST (2011) Pros and cons of phage therapy. Bacteriophage 1:111\u2013114","journal-title":"Bacteriophage"},{"key":"12_CR51","doi-asserted-by":"crossref","first-page":"11197","DOI":"10.1073\/pnas.0704624104","volume":"104","author":"TK Lu","year":"2007","unstructured":"Lu TK, Collins JJ (2007) Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 104:11197\u201311202","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12_CR52","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1073\/pnas.0800442106","volume":"106","author":"TK Lu","year":"2009","unstructured":"Lu TK, Collins JJ (2009) Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A 106:4629\u20134634","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12_CR53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/JB.46.1.57-77.1943","volume":"46","author":"SE Luria","year":"1943","unstructured":"Luria SE, Delbruck M, Anderson TF (1943) Electron microscope studies of bacterial viruses. J Bacteriol 46:57\u201377","journal-title":"J Bacteriol"},{"key":"12_CR54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/vim.2013.0128","volume":"27","author":"M Lusiak-Szelachowska","year":"2014","unstructured":"Lusiak-Szelachowska M, Zaczek M, Weber-Dabrowska B, Miedzybrodzki R, Klak M et al (2014) Phage neutralization by sera of patients receiving phage therapy. Viral Immunol 27:295\u2013304","journal-title":"Viral Immunol"},{"key":"12_CR55","first-page":"51","volume":"5","author":"MH Ly-Chatain","year":"2014","unstructured":"Ly-Chatain MH (2014) The factors affecting effectiveness of treatment in phages therapy. Front Microbiol 5:51","journal-title":"Front Microbiol"},{"key":"12_CR56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1574-6968.2009.01588.x","volume":"295","author":"F Mahichi","year":"2009","unstructured":"Mahichi F, Synnott AJ, Yamamichi K, Osada T, Tanji Y (2009) Site-specific recombination of T2 phage using IP008 long tail fiber genes provides a targeted method for expanding host range while retaining lytic activity. FEMS Microbiol Lett 295:211\u2013217","journal-title":"FEMS Microbiol Lett"},{"key":"12_CR57","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.surg.2005.02.012","volume":"137","author":"T Matsuda","year":"2005","unstructured":"Matsuda T, Freeman TA, Hilbert DW, Duff M, Fuortes M et al (2005) Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 137:639\u2013646","journal-title":"Surgery"},{"key":"12_CR58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10156-005-0408-9","volume":"11","author":"S Matsuzaki","year":"2005","unstructured":"Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T et al (2005) Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 11:211\u2013219","journal-title":"J Infect Chemother"},{"key":"12_CR59","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1128\/AAC.00602-12","volume":"56","author":"D Maura","year":"2012","unstructured":"Maura D, Galtier M, Le Bouguenec C, Debarbieux L (2012) Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine. Antimicrob Agents Chemother 56:6235\u20136242","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR60","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/eva.12196","volume":"8","author":"AH Melnyk","year":"2015","unstructured":"Melnyk AH, Wong A, Kassen R (2015) The fitness costs of antibiotic resistance mutations. Evol Appl 8:273\u2013283","journal-title":"Evol Appl"},{"key":"12_CR61","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1099\/jmm.0.071753-0","volume":"63","author":"JJ Mendes","year":"2014","unstructured":"Mendes JJ, Leandro C, Mottola C, Barbosa R, Silva FA et al (2014) In vitro design of a novel lytic bacteriophage cocktail with therapeutic potential against organisms causing diabetic foot infections. J Med Microbiol 63:1055\u20131065","journal-title":"J Med Microbiol"},{"key":"12_CR62","doi-asserted-by":"crossref","first-page":"e4944","DOI":"10.1371\/journal.pone.0004944","volume":"4","author":"M Merabishvili","year":"2009","unstructured":"Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M et al (2009) Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4:e4944","journal-title":"PLoS One"},{"key":"12_CR63","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1073\/pnas.93.8.3188","volume":"93","author":"CR Merril","year":"1996","unstructured":"Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ et al (1996) Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 93:3188\u20133192","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12_CR64","doi-asserted-by":"crossref","unstructured":"Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Fortuna W, Letkiewicz S, et al. (2012) Clinical aspects of phage therapy. Adv Virus Res, Vol 83: Bacteriophages B 83: 73\u2013121","DOI":"10.1016\/B978-0-12-394438-2.00003-7"},{"key":"12_CR65","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1101\/gr.122705.111","volume":"21","author":"S Minot","year":"2011","unstructured":"Minot S, Sinha R, Chen J, Li HZ, Keilbaugh SA et al (2011) The human gut virome: inter-individual variation and dynamic response to diet. Genome Res 21:1616\u20131625","journal-title":"Genome Res"},{"key":"12_CR66","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nature12212","volume":"499","author":"SR Modi","year":"2013","unstructured":"Modi SR, Lee HH, Spina CS, Collins JJ (2013) Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. Nature 499:219","journal-title":"Nature"},{"key":"12_CR67","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.biotechadv.2011.06.003","volume":"29","author":"Z Moradpour","year":"2011","unstructured":"Moradpour Z, Ghasemian A (2011) Modified phages: novel antimicrobial agents to combat infectious diseases. Biotechnol Adv 29:732\u2013738","journal-title":"Biotechnol Adv"},{"key":"12_CR68","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1128\/JB.186.21.7029-7031.2004","volume":"186","author":"D Nelson","year":"2004","unstructured":"Nelson D (2004) Phage taxonomy: we agree to disagree. J Bacteriol 186:7029\u20137031","journal-title":"J Bacteriol"},{"key":"12_CR69","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.tim.2015.01.006","volume":"23","author":"FL Nobrega","year":"2015","unstructured":"Nobrega FL, Costa AR, Kluskens LD, Azeredo J (2015) Revisiting phage therapy: new applications for old resources. Trends Microbiol 23:185\u2013191","journal-title":"Trends Microbiol"},{"key":"12_CR70","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1471-2180-11-195","volume":"11","author":"VD Paul","year":"2011","unstructured":"Paul VD, Sundarrajan S, Rajagopalan SS, Hariharan S, Kempashanaiah N et al (2011) Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection. BMC Microbiol 11:195","journal-title":"BMC Microbiol"},{"key":"12_CR71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/jtbi.2000.2198","volume":"208","author":"RJ Payne","year":"2001","unstructured":"Payne RJ, Jansen VA (2001) Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol 208:37\u201348","journal-title":"J Theor Biol"},{"key":"12_CR72","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s11095-010-0313-5","volume":"28","author":"JP Pirnay","year":"2011","unstructured":"Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N et al (2011) The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm Res 28:934\u2013937","journal-title":"Pharm Res"},{"key":"12_CR73","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s11095-014-1617-7","volume":"32","author":"JP Pirnay","year":"2015","unstructured":"Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N et al (2015) Quality and safety requirements for sustainable phage therapy products. Pharm Res 32:2173\u20132179","journal-title":"Pharm Res"},{"issue":"237-238","key":"12_CR74","first-page":"240","volume":"18","author":"DD Rhoads","year":"2009","unstructured":"Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS et al (2009) Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 18(237-238):240\u2013233","journal-title":"J Wound Care"},{"key":"12_CR75","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1128\/JB.182.20.5823-5831.2000","volume":"182","author":"C Sao-Jose","year":"2000","unstructured":"Sao-Jose C, Parreira R, Vieira G, Santos MA (2000) The N-terminal region of the Oenococcus oeni bacteriophage fOg44 lysin behaves as a bona fide signal peptide in Escherichia coli and as a cis-inhibitory element, preventing lytic activity on oenococcal cells. J Bacteriol 182:5823\u20135831","journal-title":"J Bacteriol"},{"key":"12_CR76","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1128\/AEM.71.8.4872-4874.2005","volume":"71","author":"D Scholl","year":"2005","unstructured":"Scholl D, Adhya S, Merril C (2005) Escherichia coli K1\u2019s capsule is a barrier to bacteriophage T7. Appl Environ Microbiol 71:4872\u20134874","journal-title":"Appl Environ Microbiol"},{"key":"12_CR77","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature11927","volume":"494","author":"KD Seed","year":"2013","unstructured":"Seed KD, Lazinski DW, Calderwood SB, Camilli A (2013) A bacteriophage encodes its own CRISPR\/Cas adaptive response to evade host innate immunity. Nature 494:489\u2013491","journal-title":"Nature"},{"key":"12_CR78","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1128\/AAC.02388-13","volume":"58","author":"DD Semler","year":"2014","unstructured":"Semler DD, Goudie AD, Finlay WH, Dennis JJ (2014) Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections. Antimicrob Agents Chemother 58:4005\u20134013","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR79","doi-asserted-by":"crossref","unstructured":"Shivshetty N, Hosamani R, Ahmed L, Oli AK, Sannauallah S, et al. (2014) Experimental protection of diabetic mice against Lethal P. aeruginosa infection by bacteriophage. Biomed Res Int 2014: 793242","DOI":"10.1155\/2014\/793242"},{"key":"12_CR80","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijmm.2005.09.002","volume":"296","author":"M Skurnik","year":"2006","unstructured":"Skurnik M, Strauch E (2006) Phage therapy: facts and fiction. Int J Med Microbiol 296:5\u201314","journal-title":"Int J Med Microbiol"},{"key":"12_CR81","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10529-007-9346-1","volume":"29","author":"M Skurnik","year":"2007","unstructured":"Skurnik M, Pajunen M, Kiljunen S (2007) Biotechnological challenges of phage therapy. Biotechnol Lett 29:995\u20131003","journal-title":"Biotechnol Lett"},{"key":"12_CR82","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00409284","volume":"92","author":"T Sozzi","year":"1973","unstructured":"Sozzi T, Maret R, Cerise L (1973) Isolation and some characteristics of 2 Micrococcus phages from Italian salami, type-Varzi. Arch Mikrobiol 92:313\u2013320","journal-title":"Arch Mikrobiol"},{"key":"12_CR83","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/07853890108995959","volume":"33","author":"A Sulakvelidze","year":"2001","unstructured":"Sulakvelidze A, Morris JG Jr (2001) Bacteriophages as therapeutic agents. Ann Med 33:507\u2013509","journal-title":"Ann Med"},{"key":"12_CR84","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.45.3.649-659.2001","volume":"45","author":"A Sulakvelidze","year":"2001","unstructured":"Sulakvelidze A, Alavidze Z, Morris JG Jr (2001) Bacteriophage therapy. Antimicrob Agents Chemother 45:649\u2013659","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR85","volume-title":"The bacteriophages","author":"WC Summers","year":"2006","unstructured":"Summers WC (2006) Phage and the early development of molecular biology. In: Calendar R (ed) The bacteriophages. Oxford University Press, New York"},{"key":"12_CR86","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.resmic.2010.09.011","volume":"161","author":"R Sunagar","year":"2010","unstructured":"Sunagar R, Patil SA, Chandrakanth RK (2010) Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice. Res Microbiol 161:854\u2013860","journal-title":"Res Microbiol"},{"key":"12_CR87","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.micinf.2014.02.011","volume":"16","author":"I Takemura-Uchiyama","year":"2014","unstructured":"Takemura-Uchiyama I, Uchiyama J, Osanai M, Morimoto N, Asagiri T et al (2014) Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice. Microbes Infect 16:512\u2013517","journal-title":"Microbes Infect"},{"key":"12_CR88","doi-asserted-by":"crossref","first-page":"BR173","DOI":"10.12659\/MSM.881844","volume":"17","author":"L Tothova","year":"2011","unstructured":"Tothova L, Celec P, Babickova J, Gajdosova J, Al-Alami H et al (2011) Phage therapy of Cronobacter-induced urinary tract infection in mice. Med Sci Monit 17:BR173\u2013BR178","journal-title":"Med Sci Monit"},{"key":"12_CR89","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1017\/S0025727300055265","volume":"36","author":"T Helvoort van","year":"1992","unstructured":"van Helvoort T (1992) Bacteriological and physiological research styles in the early controversy on the nature of the bacteriophage phenomenon. Med Hist 36:243\u2013270","journal-title":"Med Hist"},{"key":"12_CR90","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.virusres.2005.05.014","volume":"114","author":"CL Vitiello","year":"2005","unstructured":"Vitiello CL, Merril CR, Adhya S (2005) An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. Virus Res 114:101\u2013103","journal-title":"Virus Res"},{"key":"12_CR91","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1128\/AEM.00446-14","volume":"80","author":"VV Volkova","year":"2014","unstructured":"Volkova VV, Lu Z, Besser T, Grohn YT (2014) Modeling the infection dynamics of bacteriophages in enteric Escherichia coli: estimating the contribution of transduction to antimicrobial gene spread. Appl Environ Microbiol 80:4350\u20134362","journal-title":"Appl Environ Microbiol"},{"key":"12_CR92","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/ismej.2014.30","volume":"8","author":"AS Waller","year":"2014","unstructured":"Waller AS, Yamada T, Kristensen DM, Kultima JR, Sunagawa S et al (2014) Classification and quantification of bacteriophage taxa in human gut metagenomes. ISME J 8:1391\u20131402","journal-title":"ISME J"},{"key":"12_CR93","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/AAC.00635-06","volume":"51","author":"R Watanabe","year":"2007","unstructured":"Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K et al (2007) Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 51:446\u2013452","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR94","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.femsre.2003.08.001","volume":"28","author":"MG Weinbauer","year":"2004","unstructured":"Weinbauer MG (2004) Ecology of prokaryotic viruses. FEMS Microbiol Rev 28:127\u2013181","journal-title":"FEMS Microbiol Rev"},{"key":"12_CR95","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1128\/AAC.47.4.1301-1307.2003","volume":"47","author":"C Westwater","year":"2003","unstructured":"Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW et al (2003) Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 47:1301\u20131307","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR96","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1749-4486.2009.01973.x","volume":"34","author":"A Wright","year":"2009","unstructured":"Wright A, Hawkins CH, Anggard EE, Harper DR (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34:349\u2013357","journal-title":"Clin Otolaryngol"},{"key":"12_CR97","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1089\/fpd.2010.0621","volume":"7","author":"J Zhang","year":"2010","unstructured":"Zhang J, Kraft BL, Pan Y, Wall SK, Saez AC et al (2010) Development of an anti-Salmonella phage cocktail with increased host range. Foodborne Pathog Dis 7:1415\u20131419","journal-title":"Foodborne Pathog Dis"}],"container-title":["Topics in Biodiversity and Conservation","Bioprospecting"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-47935-4_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T22:19:28Z","timestamp":1658009968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-47935-4_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,13]]},"ISBN":["9783319479330","9783319479354"],"references-count":97,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-47935-4_12","relation":{},"ISSN":["1875-1288","1875-1296"],"issn-type":[{"value":"1875-1288","type":"print"},{"value":"1875-1296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,13]]}}}